

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED

精 優 藥 業 控 股 有 限 公 司\*

(incorporated in Bermuda with limited liability)

(Stock Code: 00858)

### PROFIT ALERT

This announcement is made by Extrawell Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended 31 March 2018 (the “**Management Accounts**”), the Group expects to record an increase in profit of about HK\$30 million for the year ended 31 March 2018 as compared with that for the year ended 31 March 2017. The increase in profit was primarily attributable to the decrease in loss related to fair value change of the derivative component of the Group’s investments in convertible bonds of about HK\$17 million and increase in effective interest income from investments in convertible bonds of about HK\$12 million, which are both non-cash items. Although there was a decline in the Group’s revenue by about 20% primarily attributable to significant decrease in sales of its trading segment affected by intensified competition from competing products of local manufacturers in China market and the negative impact arising from increasing regulatory scrutiny on imported products, the manufacturing segment had achieved improvement in performance for the year ended 31 March 2018.

The Company is still in the process of preparing the annual results of the Group for the year ended 31 March 2018, the information as set out above is only based on the preliminary assessment by the Board on the information currently available to it, including the Management Accounts, which have not been finalized and are subject to audit or further review by the Company’s auditor. The annual results of the Company for the year ended 31 March 2018 are expected to be published before the end of June 2018.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Extrawell Pharmaceutical Holdings Limited**  
**Xie Yi**  
*Chairman*

Hong Kong, 15 June 2018

*As at the date of this announcement, the executive directors are Dr. Xie Yi, Dr. Lou Yi, Mr. Cheng Yong, Ms. Wong Sau Kuen, Mr. Liu Kwok Wah and Mr. Lu Zhiqiang, and the independent non-executive directors are Mr. Fang Lin Hu, Mr. Xue Jing Lun and Ms. Jin Song.*

\* *For identification purpose only*